Similar Efficacy and Safety of Biosimilar Candidate IBI303 and Reference Products of Adalimumab in Patients with Ankylosing Spondylitis: Results from a Randomized, Double-Blind, Phase III Study
机构:[1]Shanghai Changzheng Hospital, Shanghai, China,[2]The First Affiliated Hospital of Bengbu Medical College, Bengbu, China,[3]The First Affiliated Hospital of Soochow University, Suzhou, China,[4]Qingdao municipal hospital, Qingdao, China,[5]The First Affiliated Hospital of Xiamen University, Xiamen, China,[6]Nanfang Hospital, Southern Medical University, Guangzhou, China,[7]Peking University People’s Hospital, Beijing, China,[8]People’s Hospital of Xinjiang Uygur Autonomous Region, Wulumuqi, China,[9]Anhui Provincial Hospital, Hefei, China,[10]Jiangsu Province Hospital, Nanjing, China,[11]Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China,[12]China-Japan Friendship Hospital, Changchun, China,[13]The Affiliated Hospital of Inner Mongolia Medical University, Huhehaote, China,[14]The First Affiliated Hospital of Shantou University Medical College, Shantou, China,[15]The First Affiliated Hospital of Anhui Medical University, Hefei, China,[16]Xuanwu Hospital Capital Medical University, Beijing, China,首都医科大学宣武医院[17]The First Affiliated Hospital of Baotou Medical College of Inner Mongolia University of Science & Technology, Baotou, China,[18]The First Affiliated Hospital of XinJiang Medical University, Wulumuqi, China,[19]Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China,[20]The First Hospital of China Medical University, Shenyang, China,[21]Innovent Biologics (Suzhou) Co. Ltd, Shanghai, China
Xu Huji,Li Zhijun,Jian Wu,et al.Similar Efficacy and Safety of Biosimilar Candidate IBI303 and Reference Products of Adalimumab in Patients with Ankylosing Spondylitis: Results from a Randomized, Double-Blind, Phase III Study[J].ARTHRITIS & RHEUMATOLOGY.2018,70:-.
APA:
Xu Huji,Li Zhijun,Jian, Wu,Qian, Xing,Shi, Guixiu...&Xiong, Wang.(2018).Similar Efficacy and Safety of Biosimilar Candidate IBI303 and Reference Products of Adalimumab in Patients with Ankylosing Spondylitis: Results from a Randomized, Double-Blind, Phase III Study.ARTHRITIS & RHEUMATOLOGY,70,
MLA:
Xu Huji,et al."Similar Efficacy and Safety of Biosimilar Candidate IBI303 and Reference Products of Adalimumab in Patients with Ankylosing Spondylitis: Results from a Randomized, Double-Blind, Phase III Study".ARTHRITIS & RHEUMATOLOGY 70.(2018):-